Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 6,236 Shares of Stock

Key Points

• Insider sale: Soleil Boughton sold 6,236 Hims & Hers shares for approximately $173,735 under a pre-arranged Rule 10b5-1 plan, reducing their holdings by 2.01% to 304,270 shares.
• Financial performance: The company reported quarterly revenue of $753.21 million, up 38.2% year over year and above estimates, but posted an adjusted loss of $0.37 per share versus the expected $0.05 loss.
• Investor outlook remains cautious: HIMS shares recently traded near $27.92, while analysts’ consensus rating was “Hold” with an average price target of $32.43; the company also faces proposed securities litigation related to alleged privacy and billing practices.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 6,236 shares of the firm's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $27.86, for a total transaction of $173,734.96. Following the sale, the insider owned 304,270 shares in the company, valued at $8,476,962.20. The trade was a 2.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Price Performance

HIMS stock traded down $0.08 during trading on Thursday, reaching $27.92. The company's stock had a trading volume of 8,214,836 shares, compared to its average volume of 24,477,230. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The company's fifty day moving average is $30.34 and its 200-day moving average is $27.51. The company has a market capitalization of $6.51 billion, a P/E ratio of -44.32 and a beta of 2.42. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health's revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.17 earnings per share. On average, research analysts expect that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bienville Capital Management LLC purchased a new position in Hims & Hers Health during the 2nd quarter valued at approximately $27,242,000. Engineers Gate Manager LP purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $232,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Hims & Hers Health during the 2nd quarter worth approximately $147,000. Baird Financial Group Inc. boosted its position in shares of Hims & Hers Health by 384.6% during the 2nd quarter. Baird Financial Group Inc. now owns 65,575 shares of the company's stock valued at $2,273,000 after acquiring an additional 52,043 shares during the last quarter. Finally, Nykredit A S bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at approximately $222,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Hims & Hers and certain executives. The proposed class covers investors who purchased shares between August 4, 2025, and July 29, 2026, with November 2, 2026, set as the lead-plaintiff deadline. ClaimsFiler shareholder alert
• Negative Sentiment: The allegations center on potentially deceptive or unlawful privacy and billing practices, including issues connected with data sharing. These claims remain allegations, but could create legal liabilities and distract management. Hagens Berman class-action announcement
• Negative Sentiment: The legal-news flow reinforces concerns already reflected in recent selling pressure, while Hims & Hers continues to report losses and has substantial balance-sheet leverage. The stock has therefore remained volatile and below its recent 50-day average.
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, offering no new bullish catalyst or meaningful change to the current analyst view. Bank of America Hold rating

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on HIMS shares. TD Cowen upped their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a "buy" rating in a research report on Wednesday, July 1st. Truist Financial boosted their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a report on Monday, August 24th. Wall Street Zen upgraded shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men's health before expanding under the Hers brand to serve women and broaden its health-care offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.